Lanreotide

Lanreotide is a synthetic cyclic octapeptide somatostatin analog. It is structurally derived from native somatostatin-14 with modifications that confer resistance to enzymatic degradation and selective binding to somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5). It is administered as Somatuline Depot in a long-acting autogel formulation that releases lanreotide gradually over approximately 4 weeks, supporting once-monthly subcutaneous injection. The autogel is a supersaturated aqueous solution that forms a depot at the injection site, providing sustained drug release without requiring polymer microspheres or other complex delivery technology. Available doses are 60, 90, and 120 mg.

The molecule's commercial pathway began at Ipsen in France in the 1990s. The original immediate-release lanreotide formulation was eventually replaced by the autogel depot, which became the dominant commercial product worldwide. The 2007 FDA approval was based on the autogel formulation for the acromegaly indication. Later indication expansions (GEP-NETs in 2014, carcinoid syndrome in 2017) extended the commercial reach into oncology.

The 2014 CLARINET trial was the registrational study for the gastroenteropancreatic neuroendocrine tumor indication. The Phase 3 trial in 204 patients shown significant improvement in progression-free survival versus placebo in patients with non-functioning, well-differentiated, locally advanced or metastatic GEP-NETs. The result established lanreotide as one of the first targeted therapies for neuroendocrine tumors with established progression-free survival benefit.

The Approved Indications

Lanreotide is approved for three distinct indications in the United States, with overlapping but related mechanisms.

Acromegaly (FDA approval August 2007). Long-term treatment of acromegaly in adults who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal is normalization of GH and IGF-1 levels. Doses are titrated based on biochemical response: typical maintenance is 90 to 120 mg every 4 weeks.

Gastroenteropancreatic neuroendocrine tumors (FDA approval December 2014). Treatment of adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival. Based on the Phase 3 CLARINET trial in 204 patients. Standard dose is 120 mg every 4 weeks.

Carcinoid syndrome (FDA approval September 2017). Treatment of adults with carcinoid syndrome. When used, it reduces the frequency of short-acting somatostatin analog rescue therapy. The carcinoid syndrome indication addresses the flushing, diarrhea, and right-sided heart disease that characterize the syndrome.

The CLARINET Trial: GEP-NET Indication

The CLARINET trial is the registrational Phase 3 study that supported the 2014 GEP-NET approval and established lanreotide as a major therapy for neuroendocrine tumors.

Trial design. Randomized, double-blind, placebo-controlled, multinational Phase 3 trial. 204 patients with non-functioning, well- or moderately-differentiated GEP-NETs that were locally advanced or metastatic. Patients received lanreotide 120 mg or placebo every 4 weeks for up to 96 weeks. Primary endpoint was progression-free survival.

Primary result. Lanreotide significantly improved progression-free survival compared with placebo. Median PFS was not reached in the lanreotide arm versus 18 months in placebo (hazard ratio 0.47, 95% CI 0.30 to 0.73, p<0.001). The progression-free survival rate at 24 months was 65 percent for lanreotide versus 33 percent for placebo.

Patient population. Included pancreatic NETs (45 percent of patients), midgut NETs (35 percent), and other primary sites. The benefit was consistent across tumor primary sites.

Tolerability. Generally well tolerated. Diarrhea and abdominal pain were the most common adverse events.

Clinical impact. CLARINET established lanreotide as a standard first-line therapy for non-functioning, well-differentiated GEP-NETs and provided the basis for routine clinical use beyond carcinoid syndrome and acromegaly.

Lanreotide acts on somatostatin receptors, predominantly SSTR2 and SSTR5, expressed on multiple cell types.

Inhibition of growth hormone secretion. SSTR2 activation on pituitary somatotrophs (GH-producing cells) inhibits GH release. This is the mechanism behind the acromegaly indication. Lanreotide reduces GH and downstream IGF-1 to normal or near-normal levels in the majority of acromegaly patients.

Inhibition of insulin and glucagon secretion. Somatostatin receptor activation on pancreatic islet cells reduces both insulin and glucagon secretion. The net effect on glucose homeostasis is variable and depends on the underlying metabolic state.

Inhibition of gastrointestinal hormones. Somatostatin receptors are expressed throughout the gut and on neuroendocrine tumor cells. SSTR activation reduces secretion of serotonin (from carcinoid tumors), gastrin (from gastrinomas), VIP (from VIPomas), and other GI hormones. This is the mechanism behind the carcinoid syndrome indication.

Anti-proliferative effects on neuroendocrine tumors. Somatostatin receptor activation on tumor cells produces direct anti-proliferative effects through G-protein-mediated signaling, cell cycle arrest, and induction of apoptosis. The anti-proliferative mechanism supports the progression-free survival benefit in GEP-NETs (CLARINET trial).

Anti-secretory effects on neuroendocrine tumor hormones. In functional neuroendocrine tumors (carcinoid syndrome, gastrinoma, VIPoma), lanreotide reduces the excessive hormone secretion that produces the syndrome's clinical manifestations.

Depot formulation pharmacokinetics. The autogel forms a depot at the subcutaneous injection site that releases lanreotide gradually over approximately 4 weeks. Peak plasma concentrations are reached within hours of injection, with sustained therapeutic levels over the dosing interval. The depot formulation is what supports the convenient monthly dosing schedule.

Lanreotide is approved for three distinct indications in the United States, with overlapping but related mechanisms.

Acromegaly (FDA approval August 2007). Long-term treatment of acromegaly in adults who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal is normalization of GH and IGF-1 levels. Doses are titrated based on biochemical response: typical maintenance is 90 to 120 mg every 4 weeks.

Gastroenteropancreatic neuroendocrine tumors (FDA approval December 2014). Treatment of adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival. Based on the Phase 3 CLARINET trial in 204 patients. Standard dose is 120 mg every 4 weeks.

Carcinoid syndrome (FDA approval September 2017). Treatment of adults with carcinoid syndrome. When used, it reduces the frequency of short-acting somatostatin analog rescue therapy. The carcinoid syndrome indication addresses the flushing, diarrhea, and right-sided heart disease that characterize the syndrome.

Regulatory status

United States (FDA). Approved for three indications: acromegaly (2007), GEP-NETs (December 2014), carcinoid syndrome (September 2017). NDA held by Ipsen Biopharmaceuticals. New pre-filled syringe approved June 2019 with redesigned features for easier administration.

European Union (EMA). Approved for the same three indications. Marketed as Somatuline Autogel in EU markets.

Other markets. Approved in approximately 70 countries globally.

Generic availability. Cipla received FDA approval for the first generic lanreotide injection in 2024, providing an AP-rated therapeutic equivalent generic version of Somatuline Depot. The generic is available in 60, 90, and 120 mg strengths.

Compounding status. Lanreotide is not on the FDA Category 2 bulks list. The active commercial product status under Ipsen and the generic approval precludes Category 2 listing.

WADA status. Lanreotide is on the WADA Prohibited List under section S2 as a GH-suppressing agent. Use in competitive sport is a doping violation. Approved clinical use through legitimate prescribing channels receives Therapeutic Use Exemptions.

Lanreotide is approved for three distinct indications in the United States, with overlapping but related mechanisms.

Acromegaly (FDA approval August 2007). Long-term treatment of acromegaly in adults who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal is normalization of GH and IGF-1 levels. Doses are titrated based on biochemical response: typical maintenance is 90 to 120 mg every 4 weeks.

Gastroenteropancreatic neuroendocrine tumors (FDA approval December 2014). Treatment of adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival. Based on the Phase 3 CLARINET trial in 204 patients. Standard dose is 120 mg every 4 weeks.

Carcinoid syndrome (FDA approval September 2017). Treatment of adults with carcinoid syndrome. When used, it reduces the frequency of short-acting somatostatin analog rescue therapy. The carcinoid syndrome indication addresses the flushing, diarrhea, and right-sided heart disease that characterize the syndrome.

The lanreotide safety profile is well characterized through 20+ years of clinical use.

Gastrointestinal effects. Dominant adverse event class. Diarrhea is the most common adverse event, occurring in approximately 50 to 60 percent of patients, mostly mild to moderate. Abdominal pain, nausea, flatulence, and steatorrhea also occur. Many GI effects relate to reduced pancreatic enzyme and biliary secretion.

Cholelithiasis. Gallstones develop in approximately 20 percent of patients on long-term somatostatin analog therapy. Reduced gallbladder motility from somatostatin receptor activation is the mechanism. Most cholelithiasis is asymptomatic.

Glucose dysregulation. Both hypoglycemia and hyperglycemia can occur. The net effect varies by patient. Acromegaly patients with diabetes mellitus often see improvement in glucose control. Some patients develop new-onset diabetes or worsening of existing diabetes.

Injection-site reactions. Common with deep subcutaneous injection. Generally mild and self-limited.

Bradycardia. Mild reduction in heart rate. Generally not clinically significant.

Hypothyroidism. Reduced TSH and free T4 in some patients. Periodic thyroid function monitoring is recommended.

Vitamin B12 malabsorption. Long-term use can produce subclinical B12 deficiency.

No new safety signals have emerged from cumulative post-marketing experience.

The safety profile is acceptable for the indicated uses, where the alternatives (uncontrolled acromegaly, progressive neuroendocrine tumor, severe carcinoid syndrome) carry higher risks.

The somatostatin analog class includes several commercial products with overlapping indications but distinct properties.

Lanreotide vs Octreotide (Sandostatin / Sandostatin LAR). The two compete head-to-head for the same indications (acromegaly, GEP-NETs, carcinoid syndrome). Octreotide is the older molecule (FDA approved 1988). Lanreotide is administered every 4 weeks; octreotide LAR is administered every 4 weeks as well, but the molecular form and depot technology differ. Direct head-to-head comparison trials are limited. Patient and prescriber preference, payer coverage, and individual response patterns drive choice between the two.

Lanreotide vs Pasireotide (Signifor). Pasireotide is a multi-receptor somatostatin analog (binds SSTR1, SSTR2, SSTR3, SSTR5). Approved for Cushing's disease and acromegaly. The broader receptor profile makes pasireotide effective in some somatostatin-resistant tumors but produces more diabetes-related side effects.

Lanreotide vs Paltusotine. Paltusotine is a newer oral small-molecule SSTR2 agonist approved by FDA in 2024 for acromegaly. Different mechanism class (oral, non-peptide). The convenience of oral administration is a major patient experience advantage. Whether oral SSTR2 agonists will displace injectable somatostatin analogs is the longer-term question in the acromegaly treatment environment.

Lanreotide vs Pegvisomant. Pegvisomant is a GH receptor antagonist (different mechanism). It does not affect tumor size or GH secretion. Used in acromegaly patients who do not respond adequately to somatostatin analogs. The two are often used in combination in difficult-to-control acromegaly.